[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Cancer Group, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":137},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100605934","phase-2-chemotherapy-with-rituximab-for-aggressive-b-nhl-in-children-and-adolescents-100605934",false,"NCT07168980","Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents","B-NHL","Inclusion Criteria:\n\n* Histology or cytologically confirmed mature B-cell NHL\u002FAL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)\n* Able to comply with scheduled follow-up and with management of toxicity\n* Signed informed consent\n\nExclusion Criteria:\n\n* Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study\n* Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.\n* Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.\n\nExclusion Criteria related to Rituximab :\n\n* Tumor cell negative for CD20\n* Prior exposure to rituximab\n* Hepatitis B carrier status history of HBV or positive serology.","ALL","18 Years",{"count":20,"type":21},87,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.",[28],"Mature B-cell Non-Hodgkin Lymphoma",[30,31,32,33],"mature B-cell non-Hodgkin lymphoma","children","adolescent","rituximab","RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":38},"2025-07-01",{"date":42,"type":21},"2030-06-30",{"name":44,"class":45},"Children's Cancer Group, China","NETWORK",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years","35 Years",{"count":57,"type":21},96,[24,25],"Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[61,62,63,64,65,66,67,68,69],"Classical Hodgkin Lymphoma","Child","Adolescent","Young Adult","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan","2026-03-17",{"date":72,"type":38},"2026-03-19",{"date":74,"type":38},"2024-09-25",{"date":76,"type":21},"2039-11-15",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100491602","phase-3-capizzi-escalating-methotrexate-versus-high-dose-methotrexate-in-children-with-newly-diagnosed-t-cell-lymphoblastic-lymphoma-t-lbl-100491602","NCT05681260","Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","Inclusion Criteria:\n\n* Newly diagnosed T-lineage lymphoblastic lymphoma (T-LBL) Stage II-IV\n\nExclusion Criteria:\n\n* Patients with Down syndrome or primary immune comprised disease.\n* Ph+ T-LBL\n* Patients must not have received any prior cytotoxic chemotherapy\n* Any steroids pretreatment for \\> 5 days in the 7 days or for \\>14 days in the 28 days before the initiation of Induction chemotherapy. The dose of prednisone or methylprednisone pretreatment does not affect eligibility. Any steroids exposure that occurred \\> 28 days before the initiation of Induction chemotherapy is allowed. Inhalation and topical steroids are not considered pretreatment. A single dose of vincristine is allowed.","12 Months",{"count":87,"type":21},200,[25],"T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%\\~85%. Two different MTX intensification strategies are used commonly: HD-MTX with leucovorin rescue, and Capizzi-style MTX without leucovorin rescue plus PEG-ASP (C-MTX). Although superior outcome of patients with T-ALL receiving C-MTX compared with HD-MTX on the AALL0434 trial, the 2 approaches had not been compared directly in patients with T-LBL. There remains controversy on PET\u002FCT interpretation in children with NHL. Large prospective studies in pediatric patients with T-LBL regarding PET\u002FCT value for this is scarce. Around 1% pediatric patients with T-LBL will not achieve remission at the end of Induction (induction failure). The optimal treatment for this small subgroup is largely unclear. The BFM HR Blocks usually are applied to these patients even though the efficacy is unknown. Novel targeted therapies are needed for use. Dasatinib is identified as a targeted therapy for T-cell ALL in preclinical drug screening.",[91],"T-cell Lymphoblastic Lymphoma",[93,94,95,96,97,98,99,100],"T-cell lymphoblastic lymphoma","Pediatric","Capizzi-style Methotrexate","High dose Methotrexate","bortezomib","treatment","survival","PET scan",{"date":72,"type":38},{"date":103,"type":38},"2023-02-06",{"date":105,"type":21},"2029-12-31",{"name":44,"class":45},2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":107},"100282634","shanghai-epidemiology-study-for-adolescents-and-children-with-cancer-100282634","NCT02959086","Shanghai Epidemiology Study for Adolescents and Children with Cancer","Inclusion Criteria:\n\n* 0-19 year-old children and adolescents.\n* Diagnosed cancer in Shanghai since January 2002.\n\nExclusion Criteria:\n\n* Patients who were lost of follow-up.\n* Patient's death wasn't caused by cancer or complications but by other accidents such as car accident, fell from a great height and so on.","0 Years","19 Years",{"count":117,"type":21},2000,"10 Years","OBSERVATIONAL","The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002.",[122],"Childhood Cancer",[124,125,126,127,128],"Epidemiology","Shanghai","Cancer","Adolescents","Children","2025-02-11",{"date":131,"type":38},"2025-02-13",{"date":133,"type":38},"2002-01",{"date":135,"type":21},"2030-01",{"name":44,"class":45},""]